{"datetime": "2020-03-03 12:39:29.427234", "filename": "2002565111", "mainterms": [{"score": 0.9785430431365967, "sentences": ["; H7 subtype; vaccine; systematic review; meta-analysis Methods :   Search strategy :", "In this systematic review, all H7 subtype vaccines, including H7N1, H7N3, H7N7, and H7N9, elicited protective vaccine-specific antibodies.33", "In the nine articles included for meta-analysis, one systematic review was at low or moderate risk of bias across most domains, with high risk in allocation in one study (Figure 2).", "vaccine cross-reactivity were retained for systematic review and meta-analysis, totaling 811 Characteristics of studies included : The characteristics of the included studies were described in Table 1.", "In addition, these H7N9 vaccines also exhibited crossreaction to H7N2, H7N7, and H7N8, as described early in this systematic review.", "A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine"], "term": "systematic review", "termType": "MED", "weight": "a"}, {"links": [{"sublinks": [{"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "influenza A"}, {"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "influenza A (H7N9)"}, {"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "virus infection"}, {"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "influenza"}, {"sentences": ["In this study, we report the meta-analysis of cross-reactive antibodies induced by H7 subtype avian influenza vaccine for the first time."], "term": "avian influenza"}, {"sentences": ["Inoculation with seasonal influenza vaccine is the major intervention currently used to prevent influenza infections."], "term": "seasonal influenza"}, {"sentences": ["However, some studies reported that there was no cross-reaction between seasonal influenza vaccine and It takes 4\u20136 months to manufacture a new vaccine54-57 and this manufacturing delay is not helpful for the prevention of infection when a novel influenza virus emerges in humans as significant infections will likely occur before a vaccine is made available."], "term": "cross infection"}], "term": "adverse drug reaction - disease"}], "score": 0.9780706167221069, "sentences": ["In general, H7 subtype influenza vaccines can produce cross- protection against other H7", "These results indicate that H7 subtype influenza vaccines, H7N1, H7N3 and H7N7 exhibit cross-protection from H7N9 viruses.", "All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears.", "None of the studies included influenza infection rates, vaccine protection rates, or described influenza-like symptoms, but serological antibody levels were included.", "Inoculation with vaccine is the major intervention currently used to prevent influenza infections.", "All assessed H7 influenza vaccines induced vaccine strain-specific protective antibodies [seroconversion rate (SCR) = 0.74, 95% CI (0.65, 0.82); seroprotection rate (SPR) = 0.81, 95% CI (0.78,", "The results showed that all H7 influenza virus vaccines, including H7N1, H7N3, H7N7 and H7N9, induced cross-reactive antibodies against other H7 subtype viruses (H7N9, H7N1, and H7N3).", "In this study, we report the meta-analysis of cross-reactive antibodies induced by H7 subtype avian influenza vaccine for the first time.", "Inoculation with seasonal influenza vaccine is the major intervention currently used to prevent influenza infections.", "(2) Inoculationwith anH7 influenza vaccine.", "These results suggest that all H7 subtype vaccines that induced effective vaccine-specific antibody responses can prevent H7 influenza infection.  ", "0.83)]. All H7 influenza virus monovalent vaccines exhibited cross-reactivity tested by hemagglutinin inhibition test (HI), microneutralization test (MN) and", "In this study, a meta-analysis of the cross-reactivity of antibodies induced by one H7 subtype influenza vaccine against other H7 subtypes was performed.", "Although other H7 influenza viruses, such as H7N1, H7N2, and H7N3, have been reported to infect humans, the patients usually showed mild to moderate clinical We further analyzed the cross-reactivity induced by H7 subtype influenza vaccines against H7N9 viruses.", "Our results showed that antibodies elicited by H7N1, H7N3, H7N7, and H7N9 vaccines have cross-protection against other H7 influenza virus, with SCR of 0.66 (0.50, 0.82) and SPR of 0.79 (0.67, 0.91), meeting vaccine production license criteria CBER and CHMP.", "(1) Healthy subjects with a description of cross-reactivity induced by an H7 influenza vaccine, regardless of nationality, race, age and followup time.", "However, it will be a challenge to produce and implement a new vaccine when a novel highly pathogenic influenza virus emerges in humans as significant infections.", "viruses.7 Stadlbauer et al.44 showed that an increase in the mean geometric increase of the cross-reaction of H7N9 influenza vaccine with H7 subtypes was 14.2, while H1, H3, H4, H14, H10, and H15 viruses were 1.3, 1.9, 3.5, 2.9, 3.5 and 5.0, respectively.", "H7N1, H7N3, H7N7, and H7N9 vaccines elicited cross-reactive antibodies against other H7 subtype influenza viruses [SCR = 0.66, 95% CI (0.50, 0.82);", "However, some studies reported that there was no cross-reaction between seasonal influenza vaccine and It takes 4\u20136 months to manufacture a new vaccine54-57 and this manufacturing delay is not helpful for the prevention of infection when a novel influenza virus emerges in humans as significant infections will likely occur before a vaccine is made available.", "A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine"], "term": "influenza vaccine", "termType": "DRG", "weight": "a"}, {"score": 0.9702482223510742, "sentences": ["In this study, a meta-analysis of the cross-reactivity of antibodies induced by one H7 subtype influenza vaccine against other H7 subtypes was performed.", "; H7 subtype; vaccine; systematic review; meta-analysis Methods :   Search strategy :", "In this study, we report the meta-analysis of cross-reactive antibodies induced by H7 subtype avian influenza vaccine for the first time.", "Interestingly, in the Madan 2017 study, the only study in this meta-analysis that included aged individual (>65), the RR was 22.8 and 23.45 for SCR and SPR, respectively, when comparing peak of the response (42/56d) to 12 months, which was much higher than those in younger adults, suggesting a big decline in antibody titers in older adults.", "In the nine articles included for meta-analysis, one systematic review was at low or moderate risk of bias across most domains, with high risk in allocation in one study (Figure 2).", "vaccine cross-reactivity were retained for systematic review and meta-analysis, totaling 811 Characteristics of studies included : The characteristics of the included studies were described in Table 1.", "The crossreactivity of antibodies was assessed using SCR and SPR in meta-analysis.", "A total of 9 articles comprising 811 human subjects were included in this meta-analysis.", "All nine studies were used to assess the pooled cross-reactivity by meta-analysis.", "A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine", "Several limitations in our meta-analysis are worthy of mentioning."], "term": "meta analysis", "termType": "MED", "weight": "a"}, {"score": 0.9677308797836304, "sentences": ["The cross-reactivity of H7 vaccines at day42/ Abbreviations: SM, statistical method; REM, random-effects model; FEM, fixed-effects model; D, day; M, month; CHMP, Committee for guidance for human medicinal products; CBER, Center for Biologics Evaluation and Research.  ", "XW and XG searched the databases, screened the eligibility of Abbreviations: SCR, seroconversion rate; SPR, seroprotection rate; SM, statistical method; REM, random-effects model; FEM, fixed-effects model; CHMP, Committee for guidance for human medicinal products; CBER, Center for Biologics Evaluation and Research.    ", "Since 2013, China has experienced five epidemics of human infection with H7N9 viruses, a significant mortality rate of 39%.1,49,58,59", "Although other H7 influenza viruses, such as H7N1, H7N2, and H7N3, have been reported to infect humans, the patients usually showed mild to moderate clinical We further analyzed the cross-reactivity induced by H7 subtype influenza vaccines against H7N9 viruses.", "A/H7N9 indicate an increased risk of pandemic of unpredictable reassortant viruses capable of transmitting from animal to humans.", "H7N9 is a novel H7 subtype influenza virus with high human mortality.", "However, it will be a challenge to produce and implement a new vaccine when a novel highly pathogenic influenza virus emerges in humans as significant infections.", "However, some studies reported that there was no cross-reaction between seasonal influenza vaccine and It takes 4\u20136 months to manufacture a new vaccine54-57 and this manufacturing delay is not helpful for the prevention of infection when a novel influenza virus emerges in humans as significant infections will likely occur before a vaccine is made available.", "A total of 9 articles comprising 811 human subjects were included in this meta-analysis.", "avian influenza virus is one of the H7 subtype viruses, which has caused severe human infections with high mortality in the past several years.1,49 Of the nine studies, five showed that H7N1, H7N3, and H7N7 elicited cross-reactive antibodies against H7N9, which were measured by HI.", "In conclusion, the recent human infections with a new avian influenza"], "term": "human", "termType": "MED", "weight": "b"}, {"score": 0.8956225514411926, "sentences": ["immunosorbent assay (ELISA) to other H7 subtype viruses."], "term": "enzyme linked immunosorbent assay", "termType": "MED", "weight": "b"}, {"links": [{"term": "endogenous compound"}], "score": 0.8831355571746826, "sentences": ["0.83)]. All H7 influenza virus monovalent vaccines exhibited cross-reactivity tested by hemagglutinin inhibition test (HI), microneutralization test (MN) and", "H7 subtype influenza viruses have similar epitopes on hemagglutinin, which can induce cross-reactive antibodies."], "term": "hemagglutinin", "termType": "DRG", "weight": "b"}, {"score": 0.8419675230979919, "sentences": ["In general, H7 subtype influenza vaccines can produce cross- protection against other H7", "These results indicate that H7 subtype influenza vaccines, H7N1, H7N3 and H7N7 exhibit cross-protection from H7N9 viruses.", "All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears.", "None of the studies included influenza infection rates, vaccine protection rates, or described influenza-like symptoms, but serological antibody levels were included.", "H7N9 is a novel H7 subtype influenza virus with high human mortality.", "Inoculation with vaccine is the major intervention currently used to prevent influenza infections.", "All assessed H7 influenza vaccines induced vaccine strain-specific protective antibodies [seroconversion rate (SCR) = 0.74, 95% CI (0.65, 0.82); seroprotection rate (SPR) = 0.81, 95% CI (0.78,", "The results showed that all H7 influenza virus vaccines, including H7N1, H7N3, H7N7 and H7N9, induced cross-reactive antibodies against other H7 subtype viruses (H7N9, H7N1, and H7N3).", "In conclusion, the recent human infections with a new avian influenza", "In this study, we report the meta-analysis of cross-reactive antibodies induced by H7 subtype avian influenza vaccine for the first time.", "Inoculation with seasonal influenza vaccine is the major intervention currently used to prevent influenza infections.", "(2) Inoculationwith anH7 influenza vaccine.", "subtype influenza virus (where enough specific antibodies can be produced).  ", "These results suggest that all H7 subtype vaccines that induced effective vaccine-specific antibody responses can prevent H7 influenza infection.  ", "0.83)]. All H7 influenza virus monovalent vaccines exhibited cross-reactivity tested by hemagglutinin inhibition test (HI), microneutralization test (MN) and", "In this study, a meta-analysis of the cross-reactivity of antibodies induced by one H7 subtype influenza vaccine against other H7 subtypes was performed.", "Although other H7 influenza viruses, such as H7N1, H7N2, and H7N3, have been reported to infect humans, the patients usually showed mild to moderate clinical We further analyzed the cross-reactivity induced by H7 subtype influenza vaccines against H7N9 viruses.", "Our results showed that antibodies elicited by H7N1, H7N3, H7N7, and H7N9 vaccines have cross-protection against other H7 influenza virus, with SCR of 0.66 (0.50, 0.82) and SPR of 0.79 (0.67, 0.91), meeting vaccine production license criteria CBER and CHMP.", "(1) Healthy subjects with a description of cross-reactivity induced by an H7 influenza vaccine, regardless of nationality, race, age and followup time.", "However, it will be a challenge to produce and implement a new vaccine when a novel highly pathogenic influenza virus emerges in humans as significant infections.", "avian influenza virus is one of the H7 subtype viruses, which has caused severe human infections with high mortality in the past several years.1,49 Of the nine studies, five showed that H7N1, H7N3, and H7N7 elicited cross-reactive antibodies against H7N9, which were measured by HI.", "H7 subtype influenza viruses have similar epitopes on hemagglutinin, which can induce cross-reactive antibodies.", "viruses.7 Stadlbauer et al.44 showed that an increase in the mean geometric increase of the cross-reaction of H7N9 influenza vaccine with H7 subtypes was 14.2, while H1, H3, H4, H14, H10, and H15 viruses were 1.3, 1.9, 3.5, 2.9, 3.5 and 5.0, respectively.", "H7N1, H7N3, H7N7, and H7N9 vaccines elicited cross-reactive antibodies against other H7 subtype influenza viruses [SCR = 0.66, 95% CI (0.50, 0.82);", "(3) One of the main outcomes: influenza infection rate, incidence of influenza-like symptoms, serological changes of cross-reactive antibodies after vaccination [SCR, SPR, Any disagreements or discrepancies were resolved by discussion or by the third reviewer.", "Generation of cross-reactivity takes advantage of the fact that the same HA subtype influenza viruses share similar epitopes.7 Antibodies elicited by these strains can bind to other viruses having similar epitopes.34-36 Phylogenetic analysis has shown a high degree of homology in the HA gene sequence of various H7", "However, some studies reported that there was no cross-reaction between seasonal influenza vaccine and It takes 4\u20136 months to manufacture a new vaccine54-57 and this manufacturing delay is not helpful for the prevention of infection when a novel influenza virus emerges in humans as significant infections will likely occur before a vaccine is made available.", "A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine"], "term": "influenza", "termType": "DIS", "weight": "a"}, {"score": 0.8303036689758301, "sentences": ["viruses.7 Stadlbauer et al.44 showed that an increase in the mean geometric increase of the cross-reaction of H7N9 influenza vaccine with H7 subtypes was 14.2, while H1, H3, H4, H14, H10, and H15 viruses were 1.3, 1.9, 3.5, 2.9, 3.5 and 5.0, respectively.", "H7N1, H7N3, H7N7, and H7N9 vaccines elicited cross-reactive antibodies against other H7 subtype influenza viruses [SCR = 0.66, 95% CI (0.50, 0.82);", "These results indicate that H7 subtype influenza vaccines, H7N1, H7N3 and H7N7 exhibit cross-protection from H7N9 viruses.", "All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears.", "Although other H7 influenza viruses, such as H7N1, H7N2, and H7N3, have been reported to infect humans, the patients usually showed mild to moderate clinical We further analyzed the cross-reactivity induced by H7 subtype influenza vaccines against H7N9 viruses.", "Our results showed that antibodies elicited by H7N1, H7N3, H7N7, and H7N9 vaccines have cross-protection against other H7 influenza virus, with SCR of 0.66 (0.50, 0.82) and SPR of 0.79 (0.67, 0.91), meeting vaccine production license criteria CBER and CHMP.", "H7N9 is a novel H7 subtype influenza virus with high human mortality.", "However, it will be a challenge to produce and implement a new vaccine when a novel highly pathogenic influenza virus emerges in humans as significant infections.", "The results showed that all H7 influenza virus vaccines, including H7N1, H7N3, H7N7 and H7N9, induced cross-reactive antibodies against other H7 subtype viruses (H7N9, H7N1, and H7N3).", "However, some studies reported that there was no cross-reaction between seasonal influenza vaccine and It takes 4\u20136 months to manufacture a new vaccine54-57 and this manufacturing delay is not helpful for the prevention of infection when a novel influenza virus emerges in humans as significant infections will likely occur before a vaccine is made available.", "subtype influenza virus (where enough specific antibodies can be produced).  ", "Generation of cross-reactivity takes advantage of the fact that the same HA subtype influenza viruses share similar epitopes.7 Antibodies elicited by these strains can bind to other viruses having similar epitopes.34-36 Phylogenetic analysis has shown a high degree of homology in the HA gene sequence of various H7", "0.83)]. All H7 influenza virus monovalent vaccines exhibited cross-reactivity tested by hemagglutinin inhibition test (HI), microneutralization test (MN) and", "avian influenza virus is one of the H7 subtype viruses, which has caused severe human infections with high mortality in the past several years.1,49 Of the nine studies, five showed that H7N1, H7N3, and H7N7 elicited cross-reactive antibodies against H7N9, which were measured by HI.", "H7 subtype influenza viruses have similar epitopes on hemagglutinin, which can induce cross-reactive antibodies."], "term": "Influenza virus", "termType": "MED", "weight": "b"}, {"score": 0.8199121952056885, "sentences": ["These results indicate that H7 subtype influenza vaccines, H7N1, H7N3 and H7N7 exhibit cross-protection from H7N9 viruses.", "High pooled SPR was found in the cross-reactivity of H7N7 vaccines against non-H7N7 viruses (H7N9 and H7N3)", "All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears.", "H7N9", "H7N9 is a novel H7 subtype influenza virus with high human mortality.", "(H7N1, H7N3, and H7N7) vaccines against H7N9 viruses were 0.69 (0.52, 0.86) and 0.85 (0.76, 0.94), respectively (Table 3, Figure 4), meeting CBER and CHMP criteria.", "The results showed that all H7 influenza virus vaccines, including H7N1, H7N3, H7N7 and H7N9, induced cross-reactive antibodies against other H7 subtype viruses (H7N9, H7N1, and H7N3).", "H7N1, H7N3, H7N7, and H7N9 viruses were used as vaccine strains.", "cross-protection of other subtype H7 vaccines against H7N9 virus, data from five articles were analyzed, involving H7N1 (both inactivated and live attenuated), H7N7 (inactivated) and H7N3 (live attenuated) vaccines.", "Since 2013, China has experienced five epidemics of human infection with H7N9 viruses, a significant mortality rate of 39%.1,49,58,59", "A/H7N9 indicate an increased risk of pandemic of unpredictable reassortant viruses capable of transmitting from animal to humans.", "Cross-reactivity between H7 subtype vaccines Systematic analysis of the nine articles, cross-reactivity of vaccines was detected in subjects vaccinated with H7N9 against H7N1, H7N2, H7N3, H7N7, and H7N8; Only one article represented cross-reactivity induced by an H7N9 vaccine against H7N1,34", "However, H7N3 vaccines displayed low cross-reactivity to non-H7N3 viruses (H7N9 and H7N1)", "Three articles35,36,39 descripted the crossreactivity induced by an H7N1 vaccine against H7N9 and H7N3 viruses.", "In this systematic review, all H7 subtype vaccines, including H7N1, H7N3, H7N7, and H7N9, elicited protective vaccine-specific antibodies.33", "Although other H7 influenza viruses, such as H7N1, H7N2, and H7N3, have been reported to infect humans, the patients usually showed mild to moderate clinical We further analyzed the cross-reactivity induced by H7 subtype influenza vaccines against H7N9 viruses.", "Our results showed that antibodies elicited by H7N1, H7N3, H7N7, and H7N9 vaccines have cross-protection against other H7 influenza virus, with SCR of 0.66 (0.50, 0.82) and SPR of 0.79 (0.67, 0.91), meeting vaccine production license criteria CBER and CHMP.", "In addition, these H7N9 vaccines also exhibited crossreaction to H7N2, H7N7, and H7N8, as described early in this systematic review.", "First, this paper only analyzed the cross-reaction between H7 subtype vaccines\uff0c or against H7N9, or H7N1 and H7N3 against H7N9, due to the limited literature.", "Cross-reactivity of H7 subtype vaccines against H7N9    ", "avian influenza virus is one of the H7 subtype viruses, which has caused severe human infections with high mortality in the past several years.1,49 Of the nine studies, five showed that H7N1, H7N3, and H7N7 elicited cross-reactive antibodies against H7N9, which were measured by HI.", "viruses.7 Stadlbauer et al.44 showed that an increase in the mean geometric increase of the cross-reaction of H7N9 influenza vaccine with H7 subtypes was 14.2, while H1, H3, H4, H14, H10, and H15 viruses were 1.3, 1.9, 3.5, 2.9, 3.5 and 5.0, respectively.", "H7N1, H7N3, H7N7, and H7N9 vaccines elicited cross-reactive antibodies against other H7 subtype influenza viruses [SCR = 0.66, 95% CI (0.50, 0.82);", "H7N1 vaccines displayed cross-reactivity to nonH7N1 viruses (H7N9)", "H7N3 against H7N1 and H7N9; H7N1 against H7N3 and H7N9.", "Two articles33,45 described cross-reactivity induced by an H7N3 vaccine against H7N9 and H7N1 viruses.", "H7N7 against H7N3 and H7N9;", "Moreover, H7N9 vaccines elicited protective antibodies against H7N1, H7N2, H7N3, H7N7, and H7N8.", "The results showed that the H7 vaccine, H7N1, H7N3, and H7N7, displayed cross-protection against H7N9, with pooled SCR of 69% and SPR of 85%."], "term": "Influenza A virus (H7N9)", "termType": "MED", "weight": "b"}, {"score": 0.8171474933624268, "sentences": ["0.83)]. All H7 influenza virus monovalent vaccines exhibited cross-reactivity tested by hemagglutinin inhibition test (HI), microneutralization test (MN) and"], "term": "hemagglutination inhibition test", "termType": "MED", "weight": "b"}, {"links": [{"sublinks": [{"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "influenza A"}, {"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "influenza A (H7N9)"}, {"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "virus infection"}, {"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "influenza"}, {"sentences": ["In this study, we report the meta-analysis of cross-reactive antibodies induced by H7 subtype avian influenza vaccine for the first time."], "term": "avian influenza"}, {"sentences": ["(3) One of the main outcomes: influenza infection rate, incidence of influenza-like symptoms, serological changes of cross-reactive antibodies after vaccination [SCR, SPR, Any disagreements or discrepancies were resolved by discussion or by the third reviewer."], "term": "cross infection"}, {"sentences": ["(3) One of the main outcomes: influenza infection rate, incidence of influenza-like symptoms, serological changes of cross-reactive antibodies after vaccination [SCR, SPR, Any disagreements or discrepancies were resolved by discussion or by the third reviewer."], "term": "infection rate"}], "term": "adverse drug reaction - disease"}, {"term": "endogenous compound"}], "score": 0.7545876502990723, "sentences": ["These results indicated that the vaccine-specific antibody levels were the highest at day 42/56 and the time point is best for analysis of the cross-reaction.    ", "SPR was defined as the percentage of the serum antibody titer \u22651:40 after vaccination.", "All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears.", "To investigate the best cross-reactivity between H7 subtype vaccines, the vaccine-specific antibody responses were assessed by random effect model.", "None of the studies included influenza infection rates, vaccine protection rates, or described influenza-like symptoms, but serological antibody levels were included.", "The RRs were greater than 1 when comparing the SCR and SPR of 42/56d to 6-month and 12-month, suggesting that antibody titers declined from the peak of response (42/56d) after the second dose (Figure 3).", "Consequently, the values of the antibody titers or fold changes were displayed and then exported into Excel files.", "All assessed H7 influenza vaccines induced vaccine strain-specific protective antibodies [seroconversion rate (SCR) = 0.74, 95% CI (0.65, 0.82); seroprotection rate (SPR) = 0.81, 95% CI (0.78,", "The results showed that all H7 influenza virus vaccines, including H7N1, H7N3, H7N7 and H7N9, induced cross-reactive antibodies against other H7 subtype viruses (H7N9, H7N1, and H7N3).", "The publication bias of specific antibody responses (RR of SCR at 24/28d vs 48/56d) was evaluated using Stata12.0 for Egger\u2019s test.", "However, the composition of vaccine can influence antibody responses.", "We first analyzed the specific antibody responses at days 21/28 (3 or 4 weeks after the first inoculation), 42/56 (3 or 4 weeks after the second inoculation), 6 months and 12 months to determine the time point for the highest SCR and SPR.", "In this study, we report the meta-analysis of cross-reactive antibodies induced by H7 subtype avian influenza vaccine for the first time.", "Interestingly, in the Madan 2017 study, the only study in this meta-analysis that included aged individual (>65), the RR was 22.8 and 23.45 for SCR and SPR, respectively, when comparing peak of the response (42/56d) to 12 months, which was much higher than those in younger adults, suggesting a big decline in antibody titers in older adults.", "For the results of antibody titers37,38 and fold changes of antibody titers39 displayed as images without digital data, images were imported into digital software (Engauge Digitizer 4.1)40 to convert the outlines into x and y coordinates.", "Statistical methods : Estimates of SCR and SPR were pooled using software.42 Comparison of sub-groups (risk ratio, RR) was performed using Review Manager 5.3.43 Egger\u2019s test was performed to evaluate the publication bias of specific antibody responses using Fail-Safe Number was calculated to evaluate cross-reactivity using formula (\u2211Z/1.64)2-k (k represents the number of studies included.", "The cross-reactivity depends on specific antibody level and affinity.", "Vaccine-specific antibody responses : Antibodies induced by certain antigen can bind to other antigen containing the same or similar epitopes, which is called crossreaction.46", "subtype influenza virus (where enough specific antibodies can be produced).  ", "These results suggest that all H7 subtype vaccines that induced effective vaccine-specific antibody responses can prevent H7 influenza infection.  ", "The RRs were greater than 1, and P < .05 when comparing the responses at day 42/56 to those at day 21/ 28, suggesting that antibody responses of two doses were higher than one dose.", "SCR was defined as the percentage of the prevaccination serum antibody titer <1:10 and post-vaccination antibody titer \u22651:40, or pre-vaccination serum antibody titer \u22651:10 and at least a four-fold increase in post-vaccination antibody titer.", "The antibody responses at day 42/56 were higher than those at day 21/28, 6-month and 12-month, indicating that two doses induced stronger antibody responses than one dose and day 42/56 is the best time for analysis of the cross-reaction.", "In this study, a meta-analysis of the cross-reactivity of antibodies induced by one H7 subtype influenza vaccine against other H7 subtypes was performed.", "Our results showed that antibodies elicited by H7N1, H7N3, H7N7, and H7N9 vaccines have cross-protection against other H7 influenza virus, with SCR of 0.66 (0.50, 0.82) and SPR of 0.79 (0.67, 0.91), meeting vaccine production license criteria CBER and CHMP.", "The highest SCR and SPR of protective antibodies were 74% and 81%, respectively, 3\u20134 weeks after the second inoculation, meeting the international vaccine licensing standards, while one does not.", "specific antibody responses elicited by the unadjuvanted vaccine.", "The crossreactivity of antibodies was assessed using SCR and SPR in meta-analysis.", "Introduction, Methods, Search strategy, H7N5 OR H7N6 OR H7N7 OR H7N10, Selection criteria, Data extraction, Assessment of study quality, Statistical methods, Results, Selection of studies, Characteristics of studies included, Methodological bias risk, Vaccine-specific antibody responses, Publication bias, Discussion, Acknowledgments, Author contributions, Funding, ORCID", "avian influenza virus is one of the H7 subtype viruses, which has caused severe human infections with high mortality in the past several years.1,49 Of the nine studies, five showed that H7N1, H7N3, and H7N7 elicited cross-reactive antibodies against H7N9, which were measured by HI.", "H7 subtype influenza viruses have similar epitopes on hemagglutinin, which can induce cross-reactive antibodies.", "vaccine-specific antibodies were analyzed between day 42/56 and day 21/28, 6 months or 12 months.  ", "H7N1, H7N3, H7N7, and H7N9 vaccines elicited cross-reactive antibodies against other H7 subtype influenza viruses [SCR = 0.66, 95% CI (0.50, 0.82);", "Since antibody responses peak in 3 or 4 weeks after vaccination, the titers of antibodies at day 21/28 and day 42/56 were used to represent the antibody response of one dose and two doses, respectively.", "Based on the results of the specific antibody responses, we analyzed the cross-reactivity of H7 vaccines at day 42/56, which was detected by HI and MN assays.", "(3) One of the main outcomes: influenza infection rate, incidence of influenza-like symptoms, serological changes of cross-reactive antibodies after vaccination [SCR, SPR, Any disagreements or discrepancies were resolved by discussion or by the third reviewer.", "Both consolidated SCR (66%) and SPR (79%) of the antibodies met vaccine production license standards, CBER and CHMP.", "Generation of cross-reactivity takes advantage of the fact that the same HA subtype influenza viruses share similar epitopes.7 Antibodies elicited by these strains can bind to other viruses having similar epitopes.34-36 Phylogenetic analysis has shown a high degree of homology in the HA gene sequence of various H7", "Our results showed that SCR [0.74 (0.65, 0.82)] and SPR [0.81 (0.78, 0.83)] of vaccine-specific antibodies were the highest at day 42/56 (two doses), meeting vaccine production licensing criteria CBER and CHMP,46\u201348 whereas one dose exhibited lower antibody responses (Table 2).", "Moreover, H7N9 vaccines elicited protective antibodies against H7N1, H7N2, H7N3, H7N7, and H7N8.", "A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine"], "term": "antibody", "termType": "DRG", "weight": "a"}, {"score": 0.7262781858444214, "sentences": ["Data extraction : Two independent reviewers extracted data from all selected studies, including participant characteristics (total number, age group), vaccine dose, adjuvant, inoculation times, vaccine strain, heterologous strain, and outcomes.", "Introduction, Methods, Search strategy, H7N5 OR H7N6 OR H7N7 OR H7N10, Selection criteria, Data extraction, Assessment of study quality, Statistical methods, Results, Selection of studies, Characteristics of studies included, Methodological bias risk, Vaccine-specific antibody responses, Publication bias, Discussion, Acknowledgments, Author contributions, Funding, ORCID"], "term": "data extraction", "termType": "MED", "weight": "b"}, {"score": 0.7163825035095215, "sentences": ["However, some studies reported that there was no cross-reaction between seasonal influenza vaccine and It takes 4\u20136 months to manufacture a new vaccine54-57 and this manufacturing delay is not helpful for the prevention of infection when a novel influenza virus emerges in humans as significant infections will likely occur before a vaccine is made available.", "H7N9 is a novel H7 subtype influenza virus with high human mortality.", "However, it will be a challenge to produce and implement a new vaccine when a novel highly pathogenic influenza virus emerges in humans as significant infections.", "All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "Influenza A virus", "termType": "MED", "weight": "b"}, {"score": 0.7100056409835815, "sentences": ["Assessment of study quality : Study quality, risk of bias, was assessed by the Cochrane Handbook", "Introduction, Methods, Search strategy, H7N5 OR H7N6 OR H7N7 OR H7N10, Selection criteria, Data extraction, Assessment of study quality, Statistical methods, Results, Selection of studies, Characteristics of studies included, Methodological bias risk, Vaccine-specific antibody responses, Publication bias, Discussion, Acknowledgments, Author contributions, Funding, ORCID"], "term": "quality control", "termType": "MED", "weight": "b"}, {"score": 0.6869928240776062, "sentences": ["Due to the limited literature, the funnel plots cannot be wisely evaluated for publication bias.", "Statistical methods : Estimates of SCR and SPR were pooled using software.42 Comparison of sub-groups (risk ratio, RR) was performed using Review Manager 5.3.43 Egger\u2019s test was performed to evaluate the publication bias of specific antibody responses using Fail-Safe Number was calculated to evaluate cross-reactivity using formula (\u2211Z/1.64)2-k (k represents the number of studies included.", "Publication bias", ": No publication bias was found (p = .841).", "The publication bias of specific antibody responses (RR of SCR at 24/28d vs 48/56d) was evaluated using Stata12.0 for Egger\u2019s test.", "Introduction, Methods, Search strategy, H7N5 OR H7N6 OR H7N7 OR H7N10, Selection criteria, Data extraction, Assessment of study quality, Statistical methods, Results, Selection of studies, Characteristics of studies included, Methodological bias risk, Vaccine-specific antibody responses, Publication bias, Discussion, Acknowledgments, Author contributions, Funding, ORCID"], "term": "publishing", "termType": "MED", "weight": "b"}, {"links": [{"sublinks": [{"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "influenza A"}, {"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "influenza A (H7N9)"}, {"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "virus infection"}, {"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "influenza"}, {"sentences": ["In this study, we report the meta-analysis of cross-reactive antibodies induced by H7 subtype avian influenza vaccine for the first time."], "term": "avian influenza"}, {"sentences": ["As such, it is likely that vaccination against one H7 subtype may be sufficient to elicit cross-reaction to several of H7 subtype viruses."], "term": "vaccination reaction"}], "term": "adverse drug reaction - disease"}], "score": 0.6685227155685425, "sentences": ["In general, H7 subtype influenza vaccines can produce cross- protection against other H7", "These results indicate that H7 subtype influenza vaccines, H7N1, H7N3 and H7N7 exhibit cross-protection from H7N9 viruses.", "The cross-reactivity of H7 vaccines at day42/ Abbreviations: SM, statistical method; REM, random-effects model; FEM, fixed-effects model; D, day; M, month; CHMP, Committee for guidance for human medicinal products; CBER, Center for Biologics Evaluation and Research.  ", "All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears.", "To investigate the best cross-reactivity between H7 subtype vaccines, the vaccine-specific antibody responses were assessed by random effect model.", "Our study confirmed the cross-reactivity between the H7 subtype vaccines, indicating that the H7 vaccines, regardless of their specific subtype, induce crossprotection against other subtypes of the H7 viruses.", "H7N9 is a novel H7 subtype influenza virus with high human mortality.", "All assessed H7 influenza vaccines induced vaccine strain-specific protective antibodies [seroconversion rate (SCR) = 0.74, 95% CI (0.65, 0.82); seroprotection rate (SPR) = 0.81, 95% CI (0.78,", "The results showed that all H7 influenza virus vaccines, including H7N1, H7N3, H7N7 and H7N9, induced cross-reactive antibodies against other H7 subtype viruses (H7N9, H7N1, and H7N3).", "The differences in SCR (a) and SPR (b) of H7 subtype", "56 was further pooled to assess the cross-protection against other H7 viruses.", "cross-protection of other subtype H7 vaccines against H7N9 virus, data from five articles were analyzed, involving H7N1 (both inactivated and live attenuated), H7N7 (inactivated) and H7N3 (live attenuated) vaccines.", "In this study, we report the meta-analysis of cross-reactive antibodies induced by H7 subtype avian influenza vaccine for the first time.", "immunosorbent assay (ELISA) to other H7 subtype viruses.", "Cross-reactivity between H7 subtype vaccines Systematic analysis of the nine articles, cross-reactivity of vaccines was detected in subjects vaccinated with H7N9 against H7N1, H7N2, H7N3, H7N7, and H7N8; Only one article represented cross-reactivity induced by an H7N9 vaccine against H7N1,34", "However, a comprehensive analysis of H7 induced cross-reactivity is lacking.  ", "These results suggest that all H7 subtype vaccines that induced effective vaccine-specific antibody responses can prevent H7 influenza infection.  ", "0.83)]. All H7 influenza virus monovalent vaccines exhibited cross-reactivity tested by hemagglutinin inhibition test (HI), microneutralization test (MN) and", "As such, it is likely that vaccination against one H7 subtype may be sufficient to elicit cross-reaction to several of H7 subtype viruses.", "In this study, a meta-analysis of the cross-reactivity of antibodies induced by one H7 subtype influenza vaccine against other H7 subtypes was performed.", "The effect of vaccine types, such as adjuvanted vs. nonadjuvanted, inactivated whole virus vs. recombinant proteins or live-attenuated vaccines, etc., on the cross-reactivity of H7 subtype vaccines is needed further clarification by large trails.", "In this systematic review, all H7 subtype vaccines, including H7N1, H7N3, H7N7, and H7N9, elicited protective vaccine-specific antibodies.33", "Although other H7 influenza viruses, such as H7N1, H7N2, and H7N3, have been reported to infect humans, the patients usually showed mild to moderate clinical We further analyzed the cross-reactivity induced by H7 subtype influenza vaccines against H7N9 viruses.", "After carefully reading full text and discussion, 9 studies identified to meet the inclusion criteria and focus on the H7 subtype", "Our results showed that antibodies elicited by H7N1, H7N3, H7N7, and H7N9 vaccines have cross-protection against other H7 influenza virus, with SCR of 0.66 (0.50, 0.82) and SPR of 0.79 (0.67, 0.91), meeting vaccine production license criteria CBER and CHMP.", "(1) Healthy subjects with a description of cross-reactivity induced by an H7 influenza vaccine, regardless of nationality, race, age and followup time.", "First, this paper only analyzed the cross-reaction between H7 subtype vaccines\uff0c or against H7N9, or H7N1 and H7N3 against H7N9, due to the limited literature.", "H7N11 OR H7 subtype) and the search strategy (vaccine).", "Cross-reactivity of H7 subtype vaccines against H7N9    ", "avian influenza virus is one of the H7 subtype viruses, which has caused severe human infections with high mortality in the past several years.1,49 Of the nine studies, five showed that H7N1, H7N3, and H7N7 elicited cross-reactive antibodies against H7N9, which were measured by HI.", "H7 subtype influenza viruses have similar epitopes on hemagglutinin, which can induce cross-reactive antibodies.", "viruses.7 Stadlbauer et al.44 showed that an increase in the mean geometric increase of the cross-reaction of H7N9 influenza vaccine with H7 subtypes was 14.2, while H1, H3, H4, H14, H10, and H15 viruses were 1.3, 1.9, 3.5, 2.9, 3.5 and 5.0, respectively.", "H7N1, H7N3, H7N7, and H7N9 vaccines elicited cross-reactive antibodies against other H7 subtype influenza viruses [SCR = 0.66, 95% CI (0.50, 0.82);", "; H7 subtype; vaccine; systematic review; meta-analysis Methods :   Search strategy :", "Based on the results of the specific antibody responses, we analyzed the cross-reactivity of H7 vaccines at day 42/56, which was detected by HI and MN assays.", "Generation of cross-reactivity takes advantage of the fact that the same HA subtype influenza viruses share similar epitopes.7 Antibodies elicited by these strains can bind to other viruses having similar epitopes.34-36 Phylogenetic analysis has shown a high degree of homology in the HA gene sequence of various H7", "All subjects were inoculated with H7 vaccines on day 0 (first dose) and day 21/28 (second dose).", "Previous studies have shown that the immune effect of H7 subtype vaccine after adding adjuvant is significantly higher than that without adjuvant,60\u201362 whichmay be the main reason for the heterogeneity of the study.", "A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine", "The results showed that the H7 vaccine, H7N1, H7N3, and H7N7, displayed cross-protection against H7N9, with pooled SCR of 69% and SPR of 85%."], "term": "1 (5 isoquinolinesulfonyl) 2 methylpiperazine", "termType": "DRG", "weight": "a"}, {"score": 0.6450884342193604, "sentences": ["(3) One of the main outcomes: influenza infection rate, incidence of influenza-like symptoms, serological changes of cross-reactive antibodies after vaccination [SCR, SPR, Any disagreements or discrepancies were resolved by discussion or by the third reviewer.", "Inoculation with vaccine is the major intervention currently used to prevent influenza infections.", "Inoculation with seasonal influenza vaccine is the major intervention currently used to prevent influenza infections."], "term": "influenza vaccination", "termType": "MED", "weight": "b"}, {"score": 0.6158166527748108, "sentences": ["All assessed H7 influenza vaccines induced vaccine strain-specific protective antibodies [seroconversion rate (SCR) = 0.74, 95% CI (0.65, 0.82); seroprotection rate (SPR) = 0.81, 95% CI (0.78,", "XW and XG searched the databases, screened the eligibility of Abbreviations: SCR, seroconversion rate; SPR, seroprotection rate; SM, statistical method; REM, random-effects model; FEM, fixed-effects model; CHMP, Committee for guidance for human medicinal products; CBER, Center for Biologics Evaluation and Research.    "], "term": "seroconversion", "termType": "MED", "weight": "b"}, {"score": 0.602061927318573, "sentences": ["Of nine, four33-36 were randomized controlled trials containing saline or placebo groups, and five37\u201339,44,45 were self-controlled clinical trials."], "term": "randomized controlled trial (topic)", "termType": "MED", "weight": "b"}, {"score": 0.5644981861114502, "sentences": ["All authors then approved the final written manuscript.    ", "Due to the limited literature, the funnel plots cannot be wisely evaluated for publication bias.", "Statistical methods : Estimates of SCR and SPR were pooled using software.42 Comparison of sub-groups (risk ratio, RR) was performed using Review Manager 5.3.43 Egger\u2019s test was performed to evaluate the publication bias of specific antibody responses using Fail-Safe Number was calculated to evaluate cross-reactivity using formula (\u2211Z/1.64)2-k (k represents the number of studies included.", "Publication bias", ": No publication bias was found (p = .841).", "The publication bias of specific antibody responses (RR of SCR at 24/28d vs 48/56d) was evaluated using Stata12.0 for Egger\u2019s test.", "Introduction, Methods, Search strategy, H7N5 OR H7N6 OR H7N7 OR H7N10, Selection criteria, Data extraction, Assessment of study quality, Statistical methods, Results, Selection of studies, Characteristics of studies included, Methodological bias risk, Vaccine-specific antibody responses, Publication bias, Discussion, Acknowledgments, Author contributions, Funding, ORCID"], "term": "publication", "termType": "MED", "weight": "b"}, {"score": 0.5435897707939148, "sentences": ["SPR was defined as the percentage of the serum antibody titer \u22651:40 after vaccination.", "SCR was defined as the percentage of the prevaccination serum antibody titer <1:10 and post-vaccination antibody titer \u22651:40, or pre-vaccination serum antibody titer \u22651:10 and at least a four-fold increase in post-vaccination antibody titer."], "term": "antibody titer", "termType": "MED", "weight": "b"}, {"score": 0.5400718450546265, "sentences": ["Introduction, Methods, Search strategy, H7N5 OR H7N6 OR H7N7 OR H7N10, Selection criteria, Data extraction, Assessment of study quality, Statistical methods, Results, Selection of studies, Characteristics of studies included, Methodological bias risk, Vaccine-specific antibody responses, Publication bias, Discussion, Acknowledgments, Author contributions, Funding, ORCID", "In the nine articles included for meta-analysis, one systematic review was at low or moderate risk of bias across most domains, with high risk in allocation in one study (Figure 2).", "Assessment of study quality : Study quality, risk of bias, was assessed by the Cochrane Handbook", "(5.1.0).41 The levels of risk of bias in the random sequence generation, the allocation concealment, the blinding of participants and personnel, the blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias (whether the baseline is comparable) were judged as \u201clow risk\u201d, \u201chigh risk\u201d and \u201cuncertainty\u201d."], "term": "risk assessment", "termType": "MED", "weight": "b"}, {"score": 0.5177773237228394, "sentences": ["However, some studies reported that there was no cross-reaction between seasonal influenza vaccine and It takes 4\u20136 months to manufacture a new vaccine54-57 and this manufacturing delay is not helpful for the prevention of infection when a novel influenza virus emerges in humans as significant infections will likely occur before a vaccine is made available.", "Both consolidated SCR (66%) and SPR (79%) of the antibodies met vaccine production license standards, CBER and CHMP.", "Our results showed that antibodies elicited by H7N1, H7N3, H7N7, and H7N9 vaccines have cross-protection against other H7 influenza virus, with SCR of 0.66 (0.50, 0.82) and SPR of 0.79 (0.67, 0.91), meeting vaccine production license criteria CBER and CHMP.", "Our results showed that SCR [0.74 (0.65, 0.82)] and SPR [0.81 (0.78, 0.83)] of vaccine-specific antibodies were the highest at day 42/56 (two doses), meeting vaccine production licensing criteria CBER and CHMP,46\u201348 whereas one dose exhibited lower antibody responses (Table 2)."], "term": "vaccine production", "termType": "MED", "weight": "b"}, {"score": 0.4901575744152069, "sentences": ["Assessment of study quality : Study quality, risk of bias, was assessed by the Cochrane Handbook", "Methodological bias risk :", "In the nine articles included for meta-analysis, one systematic review was at low or moderate risk of bias across most domains, with high risk in allocation in one study (Figure 2).", "(5.1.0).41 The levels of risk of bias in the random sequence generation, the allocation concealment, the blinding of participants and personnel, the blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias (whether the baseline is comparable) were judged as \u201clow risk\u201d, \u201chigh risk\u201d and \u201cuncertainty\u201d.", "Due to the limited literature, the funnel plots cannot be wisely evaluated for publication bias.", "Statistical methods : Estimates of SCR and SPR were pooled using software.42 Comparison of sub-groups (risk ratio, RR) was performed using Review Manager 5.3.43 Egger\u2019s test was performed to evaluate the publication bias of specific antibody responses using Fail-Safe Number was calculated to evaluate cross-reactivity using formula (\u2211Z/1.64)2-k (k represents the number of studies included.", "Publication bias", ": No publication bias was found (p = .841).", "The publication bias of specific antibody responses (RR of SCR at 24/28d vs 48/56d) was evaluated using Stata12.0 for Egger\u2019s test.", "Introduction, Methods, Search strategy, H7N5 OR H7N6 OR H7N7 OR H7N10, Selection criteria, Data extraction, Assessment of study quality, Statistical methods, Results, Selection of studies, Characteristics of studies included, Methodological bias risk, Vaccine-specific antibody responses, Publication bias, Discussion, Acknowledgments, Author contributions, Funding, ORCID", "Moreover, most studies had unclear bias risk, which might weaken the result"], "term": "statistical bias", "termType": "MED", "weight": "b"}, {"score": 0.46701204776763916, "sentences": ["Inoculation with seasonal influenza vaccine is the major intervention currently used to prevent influenza infections.", "Data extraction : Two independent reviewers extracted data from all selected studies, including participant characteristics (total number, age group), vaccine dose, adjuvant, inoculation times, vaccine strain, heterologous strain, and outcomes.", "The highest SCR and SPR of protective antibodies were 74% and 81%, respectively, 3\u20134 weeks after the second inoculation, meeting the international vaccine licensing standards, while one does not.", "Inoculation with vaccine is the major intervention currently used to prevent influenza infections.", "We first analyzed the specific antibody responses at days 21/28 (3 or 4 weeks after the first inoculation), 42/56 (3 or 4 weeks after the second inoculation), 6 months and 12 months to determine the time point for the highest SCR and SPR."], "term": "inoculation", "termType": "MED", "weight": "b"}, {"score": 0.453836053609848, "sentences": ["avian influenza virus is one of the H7 subtype viruses, which has caused severe human infections with high mortality in the past several years.1,49 Of the nine studies, five showed that H7N1, H7N3, and H7N7 elicited cross-reactive antibodies against H7N9, which were measured by HI."], "term": "avian influenza virus", "termType": "MED", "weight": "b"}, {"score": 0.45056164264678955, "sentences": ["Of nine, four33-36 were randomized controlled trials containing saline or placebo groups, and five37\u201339,44,45 were self-controlled clinical trials."], "term": "controlled clinical trial (topic)", "termType": "MED", "weight": "b"}, {"score": 0.4053717851638794, "sentences": ["In this study, we report the meta-analysis of cross-reactive antibodies induced by H7 subtype avian influenza vaccine for the first time.", "avian influenza virus is one of the H7 subtype viruses, which has caused severe human infections with high mortality in the past several years.1,49 Of the nine studies, five showed that H7N1, H7N3, and H7N7 elicited cross-reactive antibodies against H7N9, which were measured by HI.", "In conclusion, the recent human infections with a new avian influenza"], "term": "avian influenza", "termType": "DIS", "weight": "b"}, {"links": [{"sublinks": [{"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "influenza A"}, {"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "influenza A (H7N9)"}, {"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "virus infection"}, {"sentences": ["All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears."], "term": "influenza"}, {"sentences": ["In this study, we report the meta-analysis of cross-reactive antibodies induced by H7 subtype avian influenza vaccine for the first time."], "term": "avian influenza"}, {"sentences": ["Inoculation with seasonal influenza vaccine is the major intervention currently used to prevent influenza infections."], "term": "seasonal influenza"}, {"sentences": ["Among the nine articles included, Rudenko et al.33 showed that the specific response and cross-reaction of H7N3 vaccine after two doses of vaccination were low, possibly due to the unadjuvanted vaccine."], "term": "vaccination reaction"}, {"sentences": ["However, some studies reported that there was no cross-reaction between seasonal influenza vaccine and It takes 4\u20136 months to manufacture a new vaccine54-57 and this manufacturing delay is not helpful for the prevention of infection when a novel influenza virus emerges in humans as significant infections will likely occur before a vaccine is made available."], "term": "cross infection"}], "term": "adverse drug reaction - disease"}], "score": 0.40328943729400635, "sentences": ["In general, H7 subtype influenza vaccines can produce cross- protection against other H7", "These results indicated that the vaccine-specific antibody levels were the highest at day 42/56 and the time point is best for analysis of the cross-reaction.    ", "These results indicate that H7 subtype influenza vaccines, H7N1, H7N3 and H7N7 exhibit cross-protection from H7N9 viruses.", "The cross-reactivity of H7 vaccines at day42/ Abbreviations: SM, statistical method; REM, random-effects model; FEM, fixed-effects model; D, day; M, month; CHMP, Committee for guidance for human medicinal products; CBER, Center for Biologics Evaluation and Research.  ", "High pooled SPR was found in the cross-reactivity of H7N7 vaccines against non-H7N7 viruses (H7N9 and H7N3)", "All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears.", "To investigate the best cross-reactivity between H7 subtype vaccines, the vaccine-specific antibody responses were assessed by random effect model.", "The differences in vaccine-specific SCR and SPR between different time points.", "The consolidated SPR (95%CI) of H7N1 and H7N7 vaccines were 0.89 (0.86, 0.92) and 0.93 (0.81, 1.06).", "vaccine cross-reactivity were retained for systematic review and meta-analysis, totaling 811 Characteristics of studies included : The characteristics of the included studies were described in Table 1.", "None of the studies included influenza infection rates, vaccine protection rates, or described influenza-like symptoms, but serological antibody levels were included.", "Our study confirmed the cross-reactivity between the H7 subtype vaccines, indicating that the H7 vaccines, regardless of their specific subtype, induce crossprotection against other subtypes of the H7 viruses.", "Inoculation with vaccine is the major intervention currently used to prevent influenza infections.", "All assessed H7 influenza vaccines induced vaccine strain-specific protective antibodies [seroconversion rate (SCR) = 0.74, 95% CI (0.65, 0.82); seroprotection rate (SPR) = 0.81, 95% CI (0.78,", "(H7N1, H7N3, and H7N7) vaccines against H7N9 viruses were 0.69 (0.52, 0.86) and 0.85 (0.76, 0.94), respectively (Table 3, Figure 4), meeting CBER and CHMP criteria.", "The results showed that all H7 influenza virus vaccines, including H7N1, H7N3, H7N7 and H7N9, induced cross-reactive antibodies against other H7 subtype viruses (H7N9, H7N1, and H7N3).", "SPR = 0.79, 95% CI (0.67, 0.91)]. The pooled SCR (95%CI) of cross-reactivity of H7N1 and H7N3 vaccines were 0.88 (0.85, 0.91) and 0.40 (0.26, 0.54), respectively.", "H7N1, H7N3, H7N7, and H7N9 viruses were used as vaccine strains.", "However, the composition of vaccine can influence antibody responses.", "cross-protection of other subtype H7 vaccines against H7N9 virus, data from five articles were analyzed, involving H7N1 (both inactivated and live attenuated), H7N7 (inactivated) and H7N3 (live attenuated) vaccines.", "In this study, we report the meta-analysis of cross-reactive antibodies induced by H7 subtype avian influenza vaccine for the first time.", "[SCR: 0.40 (0.26, 0.54), SPR: 0.50 (0.27, 0.73)]. This may due to the unadjuvanted H7N3 vaccines used in the subjects.", "Inoculation with seasonal influenza vaccine is the major intervention currently used to prevent influenza infections.", "The H7N3 vaccines had low cross-reactivity because of insufficient vaccine- Figure 3.", "Data extraction : Two independent reviewers extracted data from all selected studies, including participant characteristics (total number, age group), vaccine dose, adjuvant, inoculation times, vaccine strain, heterologous strain, and outcomes.", "Cross-reactivity between H7 subtype vaccines Systematic analysis of the nine articles, cross-reactivity of vaccines was detected in subjects vaccinated with H7N9 against H7N1, H7N2, H7N3, H7N7, and H7N8; Only one article represented cross-reactivity induced by an H7N9 vaccine against H7N1,34", "(2) Inoculationwith anH7 influenza vaccine.", "However, H7N3 vaccines displayed low cross-reactivity to non-H7N3 viruses (H7N9 and H7N1)", "Vaccine-specific antibody responses : Antibodies induced by certain antigen can bind to other antigen containing the same or similar epitopes, which is called crossreaction.46", "These results suggest that all H7 subtype vaccines that induced effective vaccine-specific antibody responses can prevent H7 influenza infection.  ", "0.83)]. All H7 influenza virus monovalent vaccines exhibited cross-reactivity tested by hemagglutinin inhibition test (HI), microneutralization test (MN) and", "Three articles35,36,39 descripted the crossreactivity induced by an H7N1 vaccine against H7N9 and H7N3 viruses.", "In this study, a meta-analysis of the cross-reactivity of antibodies induced by one H7 subtype influenza vaccine against other H7 subtypes was performed.", "The effect of vaccine types, such as adjuvanted vs. nonadjuvanted, inactivated whole virus vs. recombinant proteins or live-attenuated vaccines, etc., on the cross-reactivity of H7 subtype vaccines is needed further clarification by large trails.", "In this systematic review, all H7 subtype vaccines, including H7N1, H7N3, H7N7, and H7N9, elicited protective vaccine-specific antibodies.33", "Although other H7 influenza viruses, such as H7N1, H7N2, and H7N3, have been reported to infect humans, the patients usually showed mild to moderate clinical We further analyzed the cross-reactivity induced by H7 subtype influenza vaccines against H7N9 viruses.", "Our results showed that antibodies elicited by H7N1, H7N3, H7N7, and H7N9 vaccines have cross-protection against other H7 influenza virus, with SCR of 0.66 (0.50, 0.82) and SPR of 0.79 (0.67, 0.91), meeting vaccine production license criteria CBER and CHMP.", "In addition, these H7N9 vaccines also exhibited crossreaction to H7N2, H7N7, and H7N8, as described early in this systematic review.", "(1) Healthy subjects with a description of cross-reactivity induced by an H7 influenza vaccine, regardless of nationality, race, age and followup time.", "The highest SCR and SPR of protective antibodies were 74% and 81%, respectively, 3\u20134 weeks after the second inoculation, meeting the international vaccine licensing standards, while one does not.", "specific antibody responses elicited by the unadjuvanted vaccine.", "Among the nine articles included, Rudenko et al.33 showed that the specific response and cross-reaction of H7N3 vaccine after two doses of vaccination were low, possibly due to the unadjuvanted vaccine.", "However, it will be a challenge to produce and implement a new vaccine when a novel highly pathogenic influenza virus emerges in humans as significant infections.", "H7N11 OR H7 subtype) and the search strategy (vaccine).", "First, this paper only analyzed the cross-reaction between H7 subtype vaccines\uff0c or against H7N9, or H7N1 and H7N3 against H7N9, due to the limited literature.", "Cross-reactivity of H7 subtype vaccines against H7N9    ", "Introduction, Methods, Search strategy, H7N5 OR H7N6 OR H7N7 OR H7N10, Selection criteria, Data extraction, Assessment of study quality, Statistical methods, Results, Selection of studies, Characteristics of studies included, Methodological bias risk, Vaccine-specific antibody responses, Publication bias, Discussion, Acknowledgments, Author contributions, Funding, ORCID", "viruses.7 Stadlbauer et al.44 showed that an increase in the mean geometric increase of the cross-reaction of H7N9 influenza vaccine with H7 subtypes was 14.2, while H1, H3, H4, H14, H10, and H15 viruses were 1.3, 1.9, 3.5, 2.9, 3.5 and 5.0, respectively.", "H7N1, H7N3, H7N7, and H7N9 vaccines elicited cross-reactive antibodies against other H7 subtype influenza viruses [SCR = 0.66, 95% CI (0.50, 0.82);", "H7N1 vaccines displayed cross-reactivity to nonH7N1 viruses (H7N9)", "; H7 subtype; vaccine; systematic review; meta-analysis Methods :   Search strategy :", "vaccine-specific antibodies were analyzed between day 42/56 and day 21/28, 6 months or 12 months.  ", "Two articles33,45 described cross-reactivity induced by an H7N3 vaccine against H7N9 and H7N1 viruses.", "Based on the results of the specific antibody responses, we analyzed the cross-reactivity of H7 vaccines at day 42/56, which was detected by HI and MN assays.", "However, some studies reported that there was no cross-reaction between seasonal influenza vaccine and It takes 4\u20136 months to manufacture a new vaccine54-57 and this manufacturing delay is not helpful for the prevention of infection when a novel influenza virus emerges in humans as significant infections will likely occur before a vaccine is made available.", "Both consolidated SCR (66%) and SPR (79%) of the antibodies met vaccine production license standards, CBER and CHMP.", "Our results showed that SCR [0.74 (0.65, 0.82)] and SPR [0.81 (0.78, 0.83)] of vaccine-specific antibodies were the highest at day 42/56 (two doses), meeting vaccine production licensing criteria CBER and CHMP,46\u201348 whereas one dose exhibited lower antibody responses (Table 2).", "Moreover, H7N9 vaccines elicited protective antibodies against H7N1, H7N2, H7N3, H7N7, and H7N8.", "All subjects were inoculated with H7 vaccines on day 0 (first dose) and day 21/28 (second dose).", "Previous studies have shown that the immune effect of H7 subtype vaccine after adding adjuvant is significantly higher than that without adjuvant,60\u201362 whichmay be the main reason for the heterogeneity of the study.", "A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine", "The results showed that the H7 vaccine, H7N1, H7N3, and H7N7, displayed cross-protection against H7N9, with pooled SCR of 69% and SPR of 85%."], "term": "vaccine", "termType": "DRG", "weight": "a"}, {"score": 0.3856946527957916, "sentences": ["Previous studies have shown that the immune effect of H7 subtype vaccine after adding adjuvant is significantly higher than that without adjuvant,60\u201362 whichmay be the main reason for the heterogeneity of the study.", "Data extraction : Two independent reviewers extracted data from all selected studies, including participant characteristics (total number, age group), vaccine dose, adjuvant, inoculation times, vaccine strain, heterologous strain, and outcomes."], "term": "adjuvant", "termType": "DRG", "weight": "b"}, {"score": 0.3765912353992462, "sentences": ["Inoculation with seasonal influenza vaccine is the major intervention currently used to prevent influenza infections.", "However, some studies reported that there was no cross-reaction between seasonal influenza vaccine and It takes 4\u20136 months to manufacture a new vaccine54-57 and this manufacturing delay is not helpful for the prevention of infection when a novel influenza virus emerges in humans as significant infections will likely occur before a vaccine is made available."], "term": "seasonal influenza", "termType": "DIS", "weight": "b"}, {"score": 0.3761278986930847, "sentences": ["(5.1.0).41 The levels of risk of bias in the random sequence generation, the allocation concealment, the blinding of participants and personnel, the blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias (whether the baseline is comparable) were judged as \u201clow risk\u201d, \u201chigh risk\u201d and \u201cuncertainty\u201d."], "term": "outcome assessment", "termType": "MED", "weight": "b"}, {"score": 0.3755558431148529, "sentences": ["Since antibody responses peak in 3 or 4 weeks after vaccination, the titers of antibodies at day 21/28 and day 42/56 were used to represent the antibody response of one dose and two doses, respectively.", "Interestingly, in the Madan 2017 study, the only study in this meta-analysis that included aged individual (>65), the RR was 22.8 and 23.45 for SCR and SPR, respectively, when comparing peak of the response (42/56d) to 12 months, which was much higher than those in younger adults, suggesting a big decline in antibody titers in older adults.", "The RRs were greater than 1 when comparing the SCR and SPR of 42/56d to 6-month and 12-month, suggesting that antibody titers declined from the peak of response (42/56d) after the second dose (Figure 3)."], "term": "antibody response", "termType": "MED", "weight": "b"}, {"score": 0.36198142170906067, "sentences": ["These results suggest that all H7 subtype vaccines that induced effective vaccine-specific antibody responses can prevent H7 influenza infection.  ", "All H7 vaccines induced crossreactive antibodies against H7N9 viruses [SCR = 0.69, 95% CI (0.52, 0.86); SPR = 0.85, 95% CI (0.76, 0.94)]. H7 vaccines can be used to limit influenza infection when a new highly pathogenic H7 virus appears.", "Since 2013, China has experienced five epidemics of human infection with H7N9 viruses, a significant mortality rate of 39%.1,49,58,59", "None of the studies included influenza infection rates, vaccine protection rates, or described influenza-like symptoms, but serological antibody levels were included.", "(3) One of the main outcomes: influenza infection rate, incidence of influenza-like symptoms, serological changes of cross-reactive antibodies after vaccination [SCR, SPR, Any disagreements or discrepancies were resolved by discussion or by the third reviewer.", "However, some studies reported that there was no cross-reaction between seasonal influenza vaccine and It takes 4\u20136 months to manufacture a new vaccine54-57 and this manufacturing delay is not helpful for the prevention of infection when a novel influenza virus emerges in humans as significant infections will likely occur before a vaccine is made available."], "term": "infection", "termType": "DIS", "weight": "b"}, {"score": 0.3494124114513397, "sentences": ["These results indicated that the vaccine-specific antibody levels were the highest at day 42/56 and the time point is best for analysis of the cross-reaction.    ", "The cross-reactivity of H7 vaccines at day42/ Abbreviations: SM, statistical method; REM, random-effects model; FEM, fixed-effects model; D, day; M, month; CHMP, Committee for guidance for human medicinal products; CBER, Center for Biologics Evaluation and Research.  ", "High pooled SPR was found in the cross-reactivity of H7N7 vaccines against non-H7N7 viruses (H7N9 and H7N3)", "To investigate the best cross-reactivity between H7 subtype vaccines, the vaccine-specific antibody responses were assessed by random effect model.", "vaccine cross-reactivity were retained for systematic review and meta-analysis, totaling 811 Characteristics of studies included : The characteristics of the included studies were described in Table 1.", "Our study confirmed the cross-reactivity between the H7 subtype vaccines, indicating that the H7 vaccines, regardless of their specific subtype, induce crossprotection against other subtypes of the H7 viruses.", "SPR = 0.79, 95% CI (0.67, 0.91)]. The pooled SCR (95%CI) of cross-reactivity of H7N1 and H7N3 vaccines were 0.88 (0.85, 0.91) and 0.40 (0.26, 0.54), respectively.", "The H7N3 vaccines had low cross-reactivity because of insufficient vaccine- Figure 3.", "Accepted 17 July 2019 KEYWORDS Cross-reactivity", "Cross-reactivity between H7 subtype vaccines Systematic analysis of the nine articles, cross-reactivity of vaccines was detected in subjects vaccinated with H7N9 against H7N1, H7N2, H7N3, H7N7, and H7N8; Only one article represented cross-reactivity induced by an H7N9 vaccine against H7N1,34", "Statistical methods : Estimates of SCR and SPR were pooled using software.42 Comparison of sub-groups (risk ratio, RR) was performed using Review Manager 5.3.43 Egger\u2019s test was performed to evaluate the publication bias of specific antibody responses using Fail-Safe Number was calculated to evaluate cross-reactivity using formula (\u2211Z/1.64)2-k (k represents the number of studies included.", "However, H7N3 vaccines displayed low cross-reactivity to non-H7N3 viruses (H7N9 and H7N1)", "The cross-reactivity depends on specific antibody level and affinity.", "However, a comprehensive analysis of H7 induced cross-reactivity is lacking.  ", "0.83)]. All H7 influenza virus monovalent vaccines exhibited cross-reactivity tested by hemagglutinin inhibition test (HI), microneutralization test (MN) and", "As such, it is likely that vaccination against one H7 subtype may be sufficient to elicit cross-reaction to several of H7 subtype viruses.", "The antibody responses at day 42/56 were higher than those at day 21/28, 6-month and 12-month, indicating that two doses induced stronger antibody responses than one dose and day 42/56 is the best time for analysis of the cross-reaction.", "In this study, a meta-analysis of the cross-reactivity of antibodies induced by one H7 subtype influenza vaccine against other H7 subtypes was performed.", "The effect of vaccine types, such as adjuvanted vs. nonadjuvanted, inactivated whole virus vs. recombinant proteins or live-attenuated vaccines, etc., on the cross-reactivity of H7 subtype vaccines is needed further clarification by large trails.", "Although other H7 influenza viruses, such as H7N1, H7N2, and H7N3, have been reported to infect humans, the patients usually showed mild to moderate clinical We further analyzed the cross-reactivity induced by H7 subtype influenza vaccines against H7N9 viruses.", "(1) Healthy subjects with a description of cross-reactivity induced by an H7 influenza vaccine, regardless of nationality, race, age and followup time.", "First, this paper only analyzed the cross-reaction between H7 subtype vaccines\uff0c or against H7N9, or H7N1 and H7N3 against H7N9, due to the limited literature.", "Among the nine articles included, Rudenko et al.33 showed that the specific response and cross-reaction of H7N3 vaccine after two doses of vaccination were low, possibly due to the unadjuvanted vaccine.", "Cross-reactivity of H7 subtype vaccines against H7N9    ", "viruses.7 Stadlbauer et al.44 showed that an increase in the mean geometric increase of the cross-reaction of H7N9 influenza vaccine with H7 subtypes was 14.2, while H1, H3, H4, H14, H10, and H15 viruses were 1.3, 1.9, 3.5, 2.9, 3.5 and 5.0, respectively.", "H7N1 vaccines displayed cross-reactivity to nonH7N1 viruses (H7N9)", "Future large-scale studies are required to carry out cross-reactivity analysis between specific subtypes.", "Two articles33,45 described cross-reactivity induced by an H7N3 vaccine against H7N9 and H7N1 viruses.", "Based on the results of the specific antibody responses, we analyzed the cross-reactivity of H7 vaccines at day 42/56, which was detected by HI and MN assays.", "Generation of cross-reactivity takes advantage of the fact that the same HA subtype influenza viruses share similar epitopes.7 Antibodies elicited by these strains can bind to other viruses having similar epitopes.34-36 Phylogenetic analysis has shown a high degree of homology in the HA gene sequence of various H7", "However, some studies reported that there was no cross-reaction between seasonal influenza vaccine and It takes 4\u20136 months to manufacture a new vaccine54-57 and this manufacturing delay is not helpful for the prevention of infection when a novel influenza virus emerges in humans as significant infections will likely occur before a vaccine is made available.", "All nine studies were used to assess the pooled cross-reactivity by meta-analysis.", "A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine"], "term": "cross reaction", "termType": "MED", "weight": "a"}, {"score": 0.34421324729919434, "term": "nonhuman", "termType": "MED", "weight": "b"}, {"score": 0.32517462968826294, "sentences": ["These results indicate that H7 subtype influenza vaccines, H7N1, H7N3 and H7N7 exhibit cross-protection from H7N9 viruses.", "The consolidated SPR (95%CI) of H7N1 and H7N7 vaccines were 0.89 (0.86, 0.92) and 0.93 (0.81, 1.06).", "(H7N1, H7N3, and H7N7) vaccines against H7N9 viruses were 0.69 (0.52, 0.86) and 0.85 (0.76, 0.94), respectively (Table 3, Figure 4), meeting CBER and CHMP criteria.", "The results showed that all H7 influenza virus vaccines, including H7N1, H7N3, H7N7 and H7N9, induced cross-reactive antibodies against other H7 subtype viruses (H7N9, H7N1, and H7N3).", "H7N1, H7N3, H7N7, and H7N9 viruses were used as vaccine strains.", "SPR = 0.79, 95% CI (0.67, 0.91)]. The pooled SCR (95%CI) of cross-reactivity of H7N1 and H7N3 vaccines were 0.88 (0.85, 0.91) and 0.40 (0.26, 0.54), respectively.", "cross-protection of other subtype H7 vaccines against H7N9 virus, data from five articles were analyzed, involving H7N1 (both inactivated and live attenuated), H7N7 (inactivated) and H7N3 (live attenuated) vaccines.", "Cross-reactivity between H7 subtype vaccines Systematic analysis of the nine articles, cross-reactivity of vaccines was detected in subjects vaccinated with H7N9 against H7N1, H7N2, H7N3, H7N7, and H7N8; Only one article represented cross-reactivity induced by an H7N9 vaccine against H7N1,34", "However, H7N3 vaccines displayed low cross-reactivity to non-H7N3 viruses (H7N9 and H7N1)", "Three articles35,36,39 descripted the crossreactivity induced by an H7N1 vaccine against H7N9 and H7N3 viruses.", "Two reviewers (Xiaoqin Gou and Xiaoxue Wu) independently searched articles in Chinese and English databases using the search strategy (H7N1 OR H7N2 Published studies were retrieved in PubMed, Cochrane Library, EMBASE, MEDLINE, CBM, and Wanfang database.", "In this systematic review, all H7 subtype vaccines, including H7N1, H7N3, H7N7, and H7N9, elicited protective vaccine-specific antibodies.33", "Although other H7 influenza viruses, such as H7N1, H7N2, and H7N3, have been reported to infect humans, the patients usually showed mild to moderate clinical We further analyzed the cross-reactivity induced by H7 subtype influenza vaccines against H7N9 viruses.", "Our results showed that antibodies elicited by H7N1, H7N3, H7N7, and H7N9 vaccines have cross-protection against other H7 influenza virus, with SCR of 0.66 (0.50, 0.82) and SPR of 0.79 (0.67, 0.91), meeting vaccine production license criteria CBER and CHMP.", "First, this paper only analyzed the cross-reaction between H7 subtype vaccines\uff0c or against H7N9, or H7N1 and H7N3 against H7N9, due to the limited literature.", "avian influenza virus is one of the H7 subtype viruses, which has caused severe human infections with high mortality in the past several years.1,49 Of the nine studies, five showed that H7N1, H7N3, and H7N7 elicited cross-reactive antibodies against H7N9, which were measured by HI.", "H7N1, H7N3, H7N7, and H7N9 vaccines elicited cross-reactive antibodies against other H7 subtype influenza viruses [SCR = 0.66, 95% CI (0.50, 0.82);", "H7N1 vaccines displayed cross-reactivity to nonH7N1 viruses (H7N9)", "H7N3 against H7N1 and H7N9; H7N1 against H7N3 and H7N9.", "Two articles33,45 described cross-reactivity induced by an H7N3 vaccine against H7N9 and H7N1 viruses.", "Moreover, H7N9 vaccines elicited protective antibodies against H7N1, H7N2, H7N3, H7N7, and H7N8.", "The results showed that the H7 vaccine, H7N1, H7N3, and H7N7, displayed cross-protection against H7N9, with pooled SCR of 69% and SPR of 85%."], "term": "Influenza A virus (H7N1)", "termType": "MED", "weight": "b"}], "timestamp": 1583239168.0, "version": "1.0"}